Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
Status:
Withdrawn
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, dose-response and safety of udenafil
25 mg, 50 mg and 75 mg every day (q.d.) for 12 weeks in the treatment of lower urinary tract
symptoms (LUTS) associated with benign prostatic hyperplasia (BPH and for the treatment of
erectile dysfunction (ED).